Key result
Disruption of CAD attenuated pressure overload-induced cardiac hypertrophy, fibrosis, and cardiac dysfunction, whereas CAD overexpression aggravated the hypertrophic response.
Why the study?
Does Caspase-activated DNase (CAD) regulate pathological cardiac hypertrophy in response to pressure overload?
Does Caspase-activated DNase (CAD) regulate pathological cardiac hypertrophy in response to pressure overload?
Caspase-activated DNase (CAD) is a necessary modulator of the hypertrophic response via the MAPK-ERK1/2 signaling pathway, suggesting it as a potential therapeutic target for pathological cardiac hypertrophy and heart failure.
CAD may mediate pressure overload hypertrophy in mice; leaves open its role in human heart failure.
Caspase-activated DNase (CAD) is a double-strand-specific endonuclease that is responsible for the cleavage of nucleosomal spacer regions and subsequent chromatin condensation during apoptosis. Given that several endonucleases (eg, DNase I, DNase II, and Endog) have been shown to regulate pathological cardiac hypertrophy, we questioned whether CAD, which is critical for the induction of DNA fragmentation, plays a pivotal role in pressure overload-elicited cardiac hypertrophy. A CAD-knockout mouse model was generated and subjected to aortic banding for 8 weeks. The extent of cardiac hypertrophy was evaluated by echocardiography and pathological and molecular analyses. Our results demonstrated that the disruption of CAD attenuated pressure overload-induced cardiac hypertrophy, fibrosis, and cardiac dysfunction. Conversely, transgenic mice with cardiac-specific overexpression of CAD showed an aggravated cardiac hypertrophic response to chronic pressure overload. Mechanistically, we discovered that the expression and activation of mitogen-activated protein kinase-extracellular signal-regulated kinase 1/2 was significantly reduced in the CAD-knockout hearts compared with the control hearts; however, they were greatly increased in the CAD-overexpressing hearts after aortic banding. Similar results were observed in ex vivo cultured neonatal rat cardiomyocytes after treatment with angiotensin II for 48 hours. These data indicate that CAD functions as a necessary modulator of the hypertrophic response by regulating the mitogen-activated protein kinase-extracellular signal-regulated kinase 1/2 signaling pathway in the heart. Our study suggests that CAD might be a novel target for the treatment of pathological cardiac hypertrophy and heart failure.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2015) studied Pathological cardiac hypertrophy. Caspase-activated DNase (CAD) disruption or overexpression vs. Control mice/hearts was evaluated on Cardiac hypertrophy, fibrosis, and cardiac dysfunction. Disruption of CAD attenuated pressure overload-induced cardiac hypertrophy, fibrosis, and cardiac dysfunction, whereas CAD overexpression aggravated the hypertrophic response.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: